Skip to Content

Taltz Approval History

Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of plaque psoriasis and psoriatic arthritis.

Development History and FDA Approval Process for Taltz

DateArticle
Dec  1, 2017Approval Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis
Mar 22, 2016Approval FDA Approves Taltz (ixekizumab) for Plaque Psoriasis
Mar  4, 2016Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements As Early As One Week Among Patients With Moderate-To-Severe Plaque Psoriasis
Nov  8, 2015Patients Show Significant Improvement In Signs And Symptoms Of Psoriatic Arthritis, Less Progression Of Structural Joint Damage When Treated With Ixekizumab For 24 Weeks
Jun 10, 2015Studies Show Psoriasis Patients Achieved Significant Levels Of Skin Clearance And Improved Quality Of Life After 12 Weeks Of Ixekizumab Treatment
Aug 21, 2014Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide